Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Melanoma cell lines from different stages of progression and their biological and molecular analyses.

Satyamoorthy K, DeJesus E, Linnenbach AJ, Kraj B, Kornreich DL, Rendle S, Elder DE, Herlyn M.

Melanoma Res. 1997 Aug;7 Suppl 2:S35-42.

PMID:
9578415
2.
3.
4.

Overexpression of mutant ras in human melanoma increases invasiveness, proliferation and anchorage-independent growth in vitro and induces tumour formation and cachexia in vivo.

Fujita M, Norris DA, Yagi H, Walsh P, Morelli JG, Weston WL, Terada N, Bennion SD, Robinson W, Lemon M, Maxwell IH, Yohn JJ.

Melanoma Res. 1999 Jun;9(3):279-91.

PMID:
10465584
5.

Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets.

Walker GJ, Flores JF, Glendening JM, Lin AH, Markl ID, Fountain JW.

Genes Chromosomes Cancer. 1998 Jun;22(2):157-63. Review.

PMID:
9598804
6.
7.
8.
9.

p16INK4a inactivation is not frequent in uncultured sporadic primary cutaneous melanoma.

Fujimoto A, Morita R, Hatta N, Takehara K, Takata M.

Oncogene. 1999 Apr 15;18(15):2527-32.

10.
11.

A new Mr 55,000 surface protein implicated in melanoma progression: association with a metastatic phenotype.

Boukerche H, Baril P, Tabone E, Bérard F, Sanhadji K, Balme B, Wolf F, Perrot H, Thomas L.

Cancer Res. 2000 Oct 15;60(20):5848-56.

12.

Functional evidence of novel tumor suppressor genes for cutaneous malignant melanoma.

Parris CN, Harris JD, Griffin DK, Cuthbert AP, Silver AJ, Newbold RF.

Cancer Res. 1999 Feb 1;59(3):516-20.

13.

Chromosome 9 deletion in sporadic and familial melanomas in vivo.

Isshiki K, Seng BA, Elder DE, Guerry D, Linnenbach AJ.

Oncogene. 1994 Jun;9(6):1649-53.

PMID:
8183559
14.

Mutational analysis of selected genes in the TGFbeta, Wnt, pRb, and p53 pathways in primary uveal melanoma.

Edmunds SC, Kelsell DP, Hungerford JL, Cree IA.

Invest Ophthalmol Vis Sci. 2002 Sep;43(9):2845-51.

PMID:
12202501
15.

New established melanoma cell lines: genetic and biochemical characterization of cell division cycle.

Vozza A, Borriello A, Criniti V, Vozza G, Della Ragione F.

J Eur Acad Dermatol Venereol. 2003 Jan;17(1):37-41.

PMID:
12602966
16.

CDKN2A mutation and deletion status in thin and thick primary melanoma.

Cachia AR, Indsto JO, McLaren KM, Mann GJ, Arends MJ.

Clin Cancer Res. 2000 Sep;6(9):3511-5.

17.

Differences in global gene expression in melanoma cell lines with and without homozygous deletion of the CDKN2A locus genes.

Bloethner S, Hemminki K, Thirumaran RK, Chen B, Mueller-Berghaus J, Ugurel S, Schadendorf D, Kumar R.

Melanoma Res. 2006 Aug;16(4):297-307.

PMID:
16845325
18.

In vitro study examining the effect of sub-lethal QS 755 nm lasers on the expression of p16INK4a on melanoma cell lines.

Chan HH, Xiang L, Leung JC, Tsang KW, Lai KN.

Lasers Surg Med. 2003;32(2):88-93.

PMID:
12561040
19.

The transcriptional repressor of p16/Ink4a, Id1, is up-regulated in early melanomas.

Polsky D, Young AZ, Busam KJ, Alani RM.

Cancer Res. 2001 Aug 15;61(16):6008-11.

20.

Interleukin-6 dependent induction of the cyclin dependent kinase inhibitor p21WAF1/CIP1 is lost during progression of human malignant melanoma.

Flørenes VA, Lu C, Bhattacharya N, Rak J, Sheehan C, Slingerland JM, Kerbel RS.

Oncogene. 1999 Jan 28;18(4):1023-32.

Supplemental Content

Support Center